Robenacoxib Crystallization to Reduce Lactam Impurities
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods for purifying Robenacoxib result in high lactam impurity levels, leading to low yield and non-compliance with VICH guidelines, making the process commercially unviable.
Innovation Solution
A process involving the dissolution of Robenacoxib in a suitable solvent, adjusting pH to 4.0-5.0, and using specific solvents for crystallization to minimize lactam impurities, followed by careful filtration and drying, yielding crystalline Robenacoxib with less than 0.1% impurity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If crude Robenacoxib is dissolved in acetone and purified using water as anti-solvent, then crystalline Robenacoxib is obtained, but lactam impurity level increases to more than 0.5%
Solution Approach 1:
The invention changes the pH parameter from acidic (2.5-3.5 in acetone) to neutral or alkaline (7.0-9.0) by adjusting with base, which prevents lactam formation while maintaining crystallization efficiency. This parameter change resolves the contradiction by eliminating the harmful impurity generation mechanism.
Solution Approach 2:
The invention introduces base (such as sodium hydroxide, potassium hydroxide, or ammonia) as an intermediary substance to adjust the pH of the acetone solution. This intermediary neutralizes the acidic environment that causes lactam formation, thereby preventing impurity generation while allowing crystallization to proceed.
2Stability of the object's composition
If Robenacoxib is purified in acidic condition, then dissolution in acetone is achieved, but Robenacoxib degrades to form lactam impurity
Solution Approach 1:
The invention changes the pH parameter from acidic (2.5-3.5) to neutral or alkaline (7.0-9.0) by adding base to the acetone solution. This parameter change stabilizes Robenacoxib by preventing acid-catalyzed hydrolysis to lactam, thereby maintaining chemical stability and eliminating impurity formation.
Solution Approach 2:
The invention converts the potentially harmful acidic environment into a beneficial neutral or alkaline environment. By adding base, the harmful acid-catalyzed degradation is prevented, and the now-neutral or alkaline conditions promote stable crystallization without lactam formation.
3Productivity
If Robenacoxib is obtained from acetone-water purification process, then crystallization is achieved, but yield and chemical purity are reduced
Solution Approach 1:
The invention changes the pH parameter to neutral or alkaline range (7.0-9.0) before crystallization, which prevents degradation and maximizes both yield and purity. This parameter optimization ensures that Robenacoxib remains stable during the crystallization process, achieving high recovery without impurity formation.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The process achieves high yield and purity of crystalline Robenacoxib, reducing lactam impurities to negligible levels, ensuring compliance with VICH guidelines and economic viability.
Implementation Method 1
crude robenacoxib is dissolved in a suitable organic solvent to obtain a clear solution
Implementation Method 2
addition of a precipitating solvent to achieve crystallization of the compound
Data Source
AI summary
The present invention relates to an improved process for purification of Robenacoxib. More particularly, the present invention relates to a process for obtaining crystalline Robenacoxib in high yield with high purity. Furthermore, the present invention provides an improved process for the purification of Robenacoxib which is essentially free of lactam impurities (less than 0.1%).